Thursday, December 18, 2014
FAIRFIELD-SUISUN, CALIFORNIA
99 CENTS

Genentech Alzheimer’s drug misses goals in studies

By
From page A5 | July 17, 2014 |

An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer’s disease, but showed some promise in the least-impaired participants who received a higher dose.

Pneumonia and deaths were more common among those receiving the drug, but researchers downplayed that. Study leader Dr. Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people.

“We’re very encouraged” by the hint of benefit for patients with milder dementia and will talk with regulators about next steps for the drug, crenezumab (cruh-NEZ-oo-mab), said a Genentech scientist, Dr. Carole Ho. The results fit with other evidence suggesting that treating earlier in the course of the disease is better, she said.

Results were revealed Wednesday at the Alzheimer’s Association International Conference in Copenhagen.

They are the latest mixed bag on treatments aimed at clearing away the sticky amyloid plaques clogging Alzheimer’s patients’ brains. About 35 million people worldwide have Alzheimer’s, the most common form of dementia. There is no cure and current treatments only temporarily ease symptoms.

Last year, an Eli Lilly & Co. medicine, solanezumab, that also sought to clear away amyloid missed main goals in two studies but combined results suggested it might help people with milder disease. It’s in further study now. Before that, bapineuzumab, a similar drug being developed by Pfizer Inc. and Johnson & Johnson, showed promise in mid-stage testing but flopped in larger, more definitive trials.

The Genentech drug has been closely watched because it targets amyloid more broadly than the other drugs do, and the California-based company has a long track record of success with many biological medicines against cancer.

Mid-stage studies aim to give some idea of safety and whether the drug is effective enough to advance to larger, more definitive studies aimed at winning market approval.

In one study, 431 patients ages 50 to 80 with mild to moderate Alzheimer’s were given crenezumab or dummy drug as shots every two weeks, or as a higher dose in infusions every four weeks for 17 months. No significant difference was seen among the groups on two widely used measures of thinking and functioning skills.

However, the 70 most mildly impaired participants who received the higher dose declined 35 percent less on the cognitive measure than the 33 mildly impaired people given dummy infusions. The difference was about 3.5 points on the roughly 70-point scale — “equivalent to six or nine months” of delay in decline, Cummings said.

This result isn’t definitive, though, and can only be considered a signal worth exploring in future research because it didn’t involve the whole group tested. And even in this mildly impaired group, the drug did not improve the second measure, ability to function in daily life.

In the second study, 73 people who showed amyloid plaques on brain imaging also were given crenezumab or dummy shots or infusions. The main outcome — levels of amyloid seen on brain imaging after treatment — will be presented at a medical conference in November. Results on cognitive function seem to mirror those in the larger study, Cummings said.

Five people given crenezumab died — one from sudden death, two from respiratory failure, one from pneumonia and one from worsening Alzheimer’s.

“We believe that the safety profile is acceptable,” because deaths do not seem related to the drug, Genentech’s Ho said. “It is not a show stopper.”

Genentech and its corporate parent, Switzerland-based Roche Holding AG, paid for the study and Cummings is a paid adviser to Genentech.

In a statement Wednesday, the Alzheimer’s Association noted that crenezumab was being tested in another study aimed at preventing the disease, and said the new results give hope it will be more successful in that setting.

___

Online:

National Institute on Aging: http://www.nia.nih.gov/Alzheimers

Patient, family info: http://www.alzheimers.gov/

Alzheimer’s Association: http://www.alz.org

 

The Associated Press

The Associated Press

LEAVE A COMMENT

Discussion | No comments

The Daily Republic does not necessarily condone the comments here, nor does it review every post. Read our full policy

.

Solano News

Solano College trustees move back ‘home’

By Susan Winlow | From Page: A1 | Gallery

 
Needs of small dog give Solano man life’s mission

By Ian Thompson | From Page: A1, 5 Comments | Gallery

 
Christmas comes early for prenatal program participants

By Susan Hiland | From Page: A2 | Gallery

Jury convicts teen for role in 2012 DeBartolo’s heist

By Jess Sullivan | From Page: A3, 3 Comments | Gallery

 
Police chief: Suisun crime up 3 percent in 2014

By Ian Thompson | From Page: A3, 2 Comments | Gallery

 
Council OKs $65,730 pact to advocate for Travis base

By Ryan McCarthy | From Page: A3

 
Fairfield pays $42,500 to settle soil suit

By Ryan McCarthy | From Page: A3

 
 
Fairfield police log: Dec. 16, 2014

By Susan Hiland | From Page: A10

Fairfield police log: Dec. 15, 2014

By Susan Hiland | From Page: A10

 
Suisun City police log: Dec. 16, 2014

By Susan Hiland | From Page: A10

Suisun City police log: Dec. 15, 2014

By Susan Hiland | From Page: A10, 1 Comment

 
.

US / World

US, Cuba patch torn relations in historic accord

By The Associated Press | From Page: A1, 1 Comment

 
Fears fanned by hackers bring down Sony film

By The Associated Press | From Page: A1, 1 Comment

 
Like Iran, secret diplomacy leads to US-Cuba thaw

By The Associated Press | From Page: A1

Pope played crucial role in US-Cuba rapprochement

By The Associated Press | From Page: A1

 
US travel industry carefully eyeing Cuba tourism

By The Associated Press | From Page: A1

US-Cuba thaw could benefit farmers, energy and travel firms

By The Associated Press | From Page: A1

 
Cubans cheer historic renewal of US relations

By The Associated Press | From Page: A1, 2 Comments

Freed American endured years of declining health

By The Associated Press | From Page: A1

 
Bay Bridge light sculpture to keep on shining

By The Associated Press | From Page: A4, 4 Comments

Study: Huge wildfire supports need for controlled burns

By The Associated Press | From Page: A5

 
A fresh setback for efforts to cure HIV infection

By The Associated Press | From Page: A5, 1 Comment

14 charged in deadly 2012 meningitis outbreak

By The Associated Press | From Page: A5

 
Study: Alcatraz inmates could have survived escape

By The Associated Press | From Page: A5

Nigerian court sentences 54 soldiers to death

By The Associated Press | From Page: A6

 
Colombian rebels announce unilateral cease-fire

By The Associated Press | From Page: A6

Russians flock to stores to pre-empt price rises

By The Associated Press | From Page: A6, 1 Comment

 
Pakistan buries victims of school massacre

By The Associated Press | From Page: A6, 1 Comment

.

Opinion

 
Crime Witness Protocol 101

By Kelvin Wade | From Page: A7, 8 Comments

 
Editorial Cartoons: Dec. 18, 2014

By Daily Republic Syndicated Content | From Page: A7

 
.

Living

Today in History: Dec. 18, 2014

By The Associated Press | From Page: A2

 
Community Calendar: Dec. 18, 2014

By Susan Hiland | From Page: A2

Horoscopes: Dec. 18, 2014

By Holiday Mathis | From Page: A9

 
My siblings don’t want to replace abusive mother’s pacemaker

By Kathy Mitchell and Marcy Sugar | From Page: A9

.

Entertainment

25 movies chosen for the National Film Registry

By The Associated Press | From Page: B4

 
Saving Private Ryan’ among films being preserved

By The Associated Press | From Page: B4

TVGrid

By Daily Republic Syndicated Content | From Page: B4

 
.

Sports

For MLB, changes in Cuba will take time to sort out

By The Associated Press | From Page: B1

 
Falcons cruise by crushers in girls basketball

By Paul Farmer | From Page: B1, 1 Comment | Gallery

49ers release McDonald amid further legal trouble

By The Associated Press | From Page: B1

 
Carr faces another tough test in rookie season

By The Associated Press | From Page: B1

Painkillers lawsuit against NFL dismissed; may be appealed

By The Associated Press | From Page: B2

 
Garcia resigns as FIFA prosecutor

By The Associated Press | From Page: B2

Chattanooga women stun No. 7 Stanford 54-46

By The Associated Press | From Page: B2 | Gallery

 
Track coach Drummond gets 8-year doping suspension

By The Associated Press | From Page: B2

Warriors’ Bogut out with knee injury vs. Thunder

By The Associated Press | From Page: B2

 
AP source: Romo close to $15M, 2-year deal with Giants

By The Associated Press | From Page: B2

Baseball monitoring White House Cuba decision

By The Associated Press | From Page: B2

 
APNewsBreak: Judge rejects NCAA concussions deal

By The Associated Press | From Page: B2

 
This date in sports history for Thursday, Dec. 18, 2014

By The Associated Press | From Page: B3

.

Business

Health care exchange sign-ups exceeding last year

By The Associated Press | From Page: B5

 
Fed to be ‘patient’ about a rate hike; stocks soar

By The Associated Press | From Page: B5

McDonald’s in Japan limits orders of fries

By The Associated Press | From Page: B5

 
Amid scrutiny, Uber says it will focus more on safety

By The Associated Press | From Page: B5

.

Obituaries

Ernest “Ernie” Moretti

By Nancy Green | From Page: A4

 
Jennie Ponce Reyes

By Nancy Green | From Page: A4

Patricia “Pat” Anne Stringfield-Pierre

By Nancy Green | From Page: A4

 
Marian L. “Chicki” Downs

By Nancy Green | From Page: A4

.

Comics

Beetle Bailey

By Daily Republic Syndicated Content | From Page: A8

 
Frank and Ernest

By Daily Republic Syndicated Content | From Page: A8

Zits

By Daily Republic Syndicated Content | From Page: A8

 
Sally Forth

By Daily Republic Syndicated Content | From Page: A8

Garfield

By Daily Republic Syndicated Content | From Page: A8

 
Peanuts

By Daily Republic Syndicated Content | From Page: A8

Dilbert

By Daily Republic Syndicated Content | From Page: A8

 
Get Fuzzy

By Daily Republic Syndicated Content | From Page: A8

For Better or Worse

By Daily Republic Syndicated Content | From Page: A8

 
B.C.

By Daily Republic Syndicated Content | From Page: A8

Rose is Rose

By Daily Republic Syndicated Content | From Page: A8

 
Blondie

By Daily Republic Syndicated Content | From Page: A8

Pickles

By Daily Republic Syndicated Content | From Page: A8

 
Baldo

By Daily Republic Syndicated Content | From Page: A8

Baby Blues

By Daily Republic Syndicated Content | From Page: A8

 
Wizard of Id

By Daily Republic Syndicated Content | From Page: A8

Word Sleuth

By Daily Republic Syndicated Content | From Page: A9

 
Crossword

By Daily Republic Syndicated Content | From Page: A9

Cryptoquote

By Daily Republic Syndicated Content | From Page: A9

 
Sudoku

By Daily Republic Syndicated Content | From Page: A9

Bridge

By Daily Republic Syndicated Content | From Page: A9